7 Result: Oracle
Oracle, Casey's General Stores and Blue Bird Set to Report Earnings: Key Metrics
December 10th, 2023
On Monday, December 11, several companies are poised to unveil their financial results, including: Oracle Corporation (NYSE: ORCL), a global technology giant, is set to disclose its second-quarter fiscal year 2024 results after the market closes.&. Read more
Scilex and Oracle: Bullish Views, Potential Upsides Unveiled
October 09th, 2023
HC Wainwright & Co. has initiated coverage on Scilex Holding Company (Nasdaq: SCLX), a pharmaceutical company, with a Buy rating and a price target of $12. Closing at $1.57 on Friday, this price target suggests a substantial potential upside of $1. Read more
Earnings Reaction Rollercoaster: Oracle Tumbles, Casey's Surges
September 11th, 2023
Oracle Corporation (NYSE: ORCL), a global technology company, reported first-quarter fiscal 2024 earnings of $1.19 per share, surpassing the consensus EPS estimate of $1.15. However, the company's quarterly revenues of $12.45 billion fell slightly be. Read more
A Preview: Oracle, Bowlero, and Mission Produce's Earnings in Focus
September 09th, 2023
Some of the companies expected to report financial results on Monday, September 11, include: Oracle Corporation (NYSE: ORCL), a global tech giant known for its database software and cloud computing solutions, is set to release its first-quarter fi. Read more
Triple Impact: iBio's Collaboration, Oracle's Strong Q4, and EVgo's Charging Network Growth Make Waves
June 12th, 2023
iBio, Inc. (NYSE American: IBIO) has partnered with the National Institute of Allergy and Infectious Diseases (NIAID) to explore the potential of the company's AI-driven epitope steering platform in developing a vaccine for Lassa fever, a severe and . Read more
23andMe: Strategic Move; Oracle, Tesla and Microsoft: PT Boost Hint at Potential Upsides
June 09th, 2023
23andMe Holding Co. (Nasdaq: ME), a leading genetic testing and personal genomics company, has disclosed in a regulatory filing with the SEC a reduction in force involving around 75 employees, representing approximately 9% of its workforce. . Read more
FibroGen Trial Disappoints, UnitedHealth Dividend Boost, Oracle and Ultragenyx Ratings Update
June 07th, 2023
FibroGen, Inc. (Nasdaq: FGEN) announced the topline data from the Phase 3 LELANTOS-1 trial, evaluating pamrevlumab as a treatment for non-ambulatory patients with Duchenne Muscular Dystrophy (DMD) on background corticosteroids. Unfortunately. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024Key Metrics: CyberArk Software, Hudbay Minerals, and Sonos Earnings Due
November 11th, 2024Earnings: What to Expect from Occidental Petroleum, Rocket Lab, and CAE
November 10th, 2024Earnings Countdown: Home Depot, Sea Limited, and Natera in the Spotlight
November 10th, 2024Ahead of Earnings: DoorDash, MetLife, and Exelon in the Spotlight
October 27th, 2024
Member Login